BioHarvest Sciences Inc (BHST) Fair Value & Analysis
Consumer Defensive · US · Market cap $74.4M
Fair value as of: Jun 25, 2026
Analysis
BioHarvest Sciences Inc (BHST) currently trades at $3.10, while our model-based Fair Value estimate is $0.3700 — implying the stock looks roughly 88.1% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouv…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is BioHarvest Sciences Inc (BHST) undervalued?
What is the fair value of BHST?
What is the quality score of BHST?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.